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RESEARCH ARTICLE
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Abstract
Mitochondrial dysfunction activates the mitochondrial retrograde signaling pathway, result-
ing in large scale changes in gene expression. Mitochondrial retrograde signaling in neurons
is poorly understood and whether retrograde signaling contributes to cellular dysfunction or
is protective is unknown. We show that inhibition of Ras-ERK-ETS signaling partially
reverses the retrograde transcriptional response to alleviate neuronal mitochondrial dys-
function. We have developed a novel genetic screen to identify genes that modify mitochon-
drial dysfunction in Drosophila. Knock-down of one of the genes identified in this screen, the
Ras-ERK-ETS pathway transcription factor Aop, alleviates the damaging effects of mito-
chondrial dysfunction in the nervous system. Inhibition of Ras-ERK-ETS signaling also
restores function in Drosophila models of human diseases associated with mitochondrial
dysfunction. Importantly, Ras-ERK-ETS pathway inhibition partially reverses the mitochon-
drial retrograde transcriptional response. Therefore, mitochondrial retrograde signaling
likely contributes to neuronal dysfunction through mis-regulation of gene expression.
Author summary
Loss of mitochondrial function activates the mitochondrial retrograde signaling pathway
resulting in large scale changes in nuclear gene transcription. Very little is known about
retrograde signaling in the nervous system and how the transcriptional changes affect
neuronal function. Here we identify Ras-ERK-ETS signaling as a novel mitochondrial ret-
rograde signaling pathway in the Drosophila nervous system. Inhibition of Ras-ERK-ETS
signaling improves neuronal function in Drosophila models of mitochondrial disease. Tar-
geting Ras-ERK-ETS signaling may therefore have therapeutic potential in mitochondrial
disease patients. Using a transcriptomic approach, we find that inhibition of Ras-ERK-
ETS signaling partially reverses the mitochondrial retrograde transcriptional response.
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Surprisingly therefore, the mitochondrial retrograde transcriptional response contributes
to neuronal dysfunction.
Introduction
The use of ATP as a universal currency of energy transfer makes this molecule essential for
life. ATP is generated either by glycolysis in the cytosol, or through the action of the tricarbox-
ylic acid (TCA) cycle and β-oxidation of fatty acids coupled to oxidative phosphorylation
(OXPHOS) in mitochondria. The mitochondrial electron transport chain (ETC) couples the
transfer of electrons to the pumping of protons into the inter-membrane space [1]. This creates
a membrane potential (ΔC), which is used by the mitochondrial ATP synthase to convert
ADP to ATP [2]. Under normal aerobic conditions mitochondria use OXPHOS to generate
the majority of cellular ATP. Mitochondria also metabolize fatty acids, synthesize amino acids,
buffer cellular calcium ions (Ca2+), produce the majority of cellular reactive oxygen species,
synthesise iron-sulphur clusters and mediate programmed cell death.
Mitochondria are abundant in almost every cell type and are particularly important in the
nervous system. During nervous system development neural stem cell progenitors use mainly
glycolytic metabolism, but upon differentiation into neurons switch to become dependent on
OXPHOS for ATP [3, 4]. Mature neurons must maintain their membrane potential through
the action of ATP dependent sodium potassium pumps and so are vitally dependent on mito-
chondrial function. Failure of mitochondria and breakdown of the cellular power supply can
lead to human disease [5, 6]. Primary mitochondrial diseases are caused by mutations in mito-
chondrial genes, either in the nuclear or mitochondrial genome [7]. These diseases are rare,
but can be severe and debilitating, often affecting the nervous system or muscle. The mito-
chondrial disease Leigh syndrome, caused by mutations in subunits of mitochondrial ETC
complex I or IV, causes degeneration of the nervous system and death in infants [8].
Mitochondrial dysfunction is also strongly implicated in neurodegenerative diseases and
may be a common pathway in Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral
sclerosis and Huntington’s disease [9]. Reduced mitochondrial ETC complex I activity in the
substantia nigra pars compacta is a hallmark of Parkinson’s disease and toxins that inhibit
complex I cause dopaminergic neuron cell death and parkinsonian phenotypes in humans and
rodent models [10–14]. Moreover, mutations in two genes involved in mitochondrial quality
control, PINK1 and Parkin, cause familial Parkinson’s disease [15]. There is also evidence sup-
porting a role for mitochondrial dysfunction in Alzheimer’s, as patients have been shown to
have mitochondrial ETC complex IV and V deficits and mitochondrial DNA mutations have
been associated with this disease [16–20].
Cells respond to changes in mitochondrial function by altering nuclear gene expression, a
process known as mitochondrial retrograde signaling [21–23]. The mechanism of retrograde
signaling varies depending on the organism and cell type. In yeast the retrograde response is
triggered by decreased glutamate, whose synthesis is reduced due to failure of the TCA cycle to
synthesise α-ketoglutarate, the precursor of glutamate [24]. This retrograde signaling pathway
culminates in the partial dephosphorylation of the transcription factor Rtg3 which, together
with its binding partner Rtg1, relocalises to the nucleus to activate gene expression [25]. In
other contexts, mitochondrial dysfunction can trigger a retrograde signaling pathway known
as the mitochondrial unfolded protein response (UPRmt). When activated, the UPRmt induces
the expression of nuclear encoded mitochondrial chaperone proteins and proteases [26]. In C.
elegans, activating transcription factor associated with stress-1 (ATFS-1) is normally localised
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to mitochondria, but upon mitochondrial dysfunction a fraction of ATFS-1 localises to the
nucleus where it regulates the expression of UPRmt genes [27, 28].
ATFS-1 is not conserved in mammals and the RTG genes are not present in metazoans, but
analogous retrograde signaling pathways have been identified that enable mitochondria to
reprogram nuclear gene expression [29, 30]. Transcriptional studies have shown that mito-
chondrial dysfunction elicits large scale changes in nuclear gene expression in diverse cell
types in a range of model systems [22, 23, 31]. However, the molecular basis of mitochondrial
signaling is still poorly understood, particularly in the nervous system [29, 30]. Importantly, it
is not known whether the retrograde transcriptional response contributes to mitochondrial
dysfunction phenotypes or is protective. To address these questions, we performed a genetic
screen and identified 30 genes that modify mitochondrial dysfunction in the Drosophila wing,
implicating several new pathways in the mitochondrial retrograde response. Manipulation of
one of the identified pathways, Ras-ERK-ETS signaling, also alleviates the effects of mitochon-
drial dysfunction in the Drosophila nervous system. Transcriptomic and functional analyses
suggest that mitochondrial retrograde signaling is reversed and transcriptionally repro-
grammed by Ras-ERK-ETS inhibition to restore neuronal function.
Results
Knock-down and overexpression of TFAM cause mitochondrial
dysfunction and activate mitochondrial retrograde signaling in the
Drosophila wing
Mitochondrial retrograde signaling is activated in response to mitochondrial dysfunction. To
induce mitochondrial dysfunction, we manipulated the expression levels of the mitochondrial
DNA binding protein/transcription factor TFAM. TFAM expression is essential for mitochon-
drial DNA maintenance (S1A Fig) and gene expression, but overexpression of TFAM in mice
and human cells also causes reduced mitochondrial gene transcription and mitochondrial dys-
function [32–35]. In Drosophila, both ubiquitous TFAM knock-down (S1B–S1E Fig) or
TFAM overexpression [36] cause reduced mitochondrial gene expression and lethality at the
larval stage. To develop a rapid, genetically modifiable assay for mitochondrial dysfunction in
vivo we tested TFAM knock-down or TFAM overexpression in the wing using MS1096-Gal4.
Strong TFAM overexpression in the wing causes late pupal lethality, while weak TFAM over-
expression or TFAM knock-down (using several independent RNAi transgenes) results in a
curved adult wing phenotype (Fig 1B, S1F, S1G, S1J–S1L Fig). Importantly, the TFAM knock-
down curved wing phenotype is enhanced by heterozygosity for a loss-of-function mutation in
TFAM (TFAMc01716) (Fig 1C, S1H Fig) and almost completely rescued by co-expression of
TFAM (S1M–S1P Fig), proving that this RNAi phenotype is a result of reduced TFAM expres-
sion. Although neither TFAM knock-down or overexpression change ATP levels (S2A–S2K
Fig), or reactive oxygen species (ROS) (S2L–S2S Fig) in the developing wing, both cause
reduced mitochondrial numbers and increased apoptosis (Fig 1D–1G, S2T–S2X Fig).
We previously showed that the gene Thor, encoding the eukaryotic initiation factor 4E
binding protein (4E-BP), is a mitochondrial retrograde signaling response gene in neurons
[36]. Both knock-down and overexpression of TFAM in the wing imaginal disc cause
increased Thor expression (Fig 1H–1K). TFAM overexpression causes a strong increase in
Thor expression throughout and beyond the dorsal compartment, while TFAM knock-down
causes increased Thor expression in discreet patches within the dorsal compartment (Fig 1H–
1K). As a result, using qRT-PCR from whole wing discs we could only detect increased Thor
expression, or increased expression of the mitochondrial unfolded response pathway target
gene Hsp22 [37] with TFAM overexpression (S2Y and S2Z Fig). These data show that
Ras pathway and mitochondrial retrograde signaling
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mitochondrial dysfunction caused by TFAM knock-down and TFAM overexpression activate
mitochondrial retrograde signaling in the wing.
In order to perform a genetic screen for modifiers of mitochondrial retrograde signaling,
flies were generated that stably express the TFAM RNAi transgene, together with the
Fig 1. Knock-down of TFAM in the wing causes a mitochondrial dysfunction sensitised phenotype. (A) A control male fly hemizygous for
MS1096-Gal4 has straight wings. (B) Knock-down of TFAM (4217R-1) in the dorsal compartment of the wing using MS1096-Gal4 causes a slightly
curved wing in male flies. (C) Knock-down of TFAM (4217R-1) using MS1096-Gal4 in a male fly heterozygous for TFAMc01716 enhances the wing curve
to approximately 45˚. (D-F) Compared to a wing disc from a control larva hemizygous for MS1096-Gal4 (D), cleaved Drosophila effector caspase (Dcp1)
expression is increased by knock-down of TFAM (4217R-1) in a TFAMc01716 heterozygous background (E) and by TFAM overexpression (F) in the
dorsal compartment of the wing disc where MS1096-Gal4 expression is highest. (G) Quantification of Dcp1 expression. (H-J) β-Gal antibody staining
for Thor-lacZ expression in a wing disc from a control larva hemizygous for MS1096-Gal4 (H), or with knock-down of TFAM (4217R-1) in a
TFAMc01716 heterozygous background (I), or TFAM overexpression (J). (K) β-Gal staining intensity (gray value) along a line placed across the dorsal
compartment (dashed lines in H-J) for four wing discs for each condition. Data are represented as mean +/- SEM, p0.001. (L,M) Knock-down of
Pink1 (JF01672) (L), or overexpression of parkin (M), enhances the curved wing phenotype in MitoMod flies. Average wing tip angles (n = 3–4) ± S.D
are shown, Pink1 knock-down and parkin overexpression phenotypes are significantly different to the MitoMod control (p<0.01).
https://doi.org/10.1371/journal.pgen.1007567.g001
Ras pathway and mitochondrial retrograde signaling
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TFAMc01716 mutation, in the wing. These flies, referred to as ‘MitoMod’ for ‘Mitochondrial
Modifier’, have a distinctive ~45˚ curve at the tip of the wing (Fig 1C). To test the sensitivity of
MitoMod flies to mitochondrial perturbation they were crossed to lines carrying RNAi or
overexpression transgenes for genes associated with familial Parkinson’s disease that have
mitochondrial associated functions. Transgenes that cause a wing phenotype when expressed
on their own were excluded to avoid additive effects (S1 Table). Overexpression or knock-
down of Pink1, overexpression of parkin, knock-down of Lrrk and overexpression and knock-
down of DJ-1α and DJ-1β all enhance the MitoMod wing phenotype (Fig 1L and 1M, S3 Fig
and S1 Table). Therefore, the MitoMod wing phenotype provides a sensitised background for
identifying mitochondrial retrograde signaling genes in vivo.
A genetic screen for genes that modify mitochondrial retrograde signaling
identifies Aop
MitoMod flies were used to perform a genetic modifier screen of 646 RNAi lines, targeting 579
genes (Fig 2A). This RNAi collection was enriched for lines that target genes expressed in the
nervous system and genes encoding chromatin remodelling factors (S2 Table). RNAi lines that
cause a phenotype when expressed alone in the wing were excluded (S2 Table), to avoid addi-
tive effects with the MitoMod wing phenotype. Stringent criteria were used to identify interact-
ing genes: only RNAi lines that caused a strong reproducible enhancement or suppression,
which was also replicated by an independent RNAi line targeting the same gene were classed
as hits. 25 genes were identified that enhance the MitoMod wing phenotype (Fig 2F–2I, S3
Table). Gene ontology (GO) analysis shows that these genes are involved in a range of biologi-
cal processes and functions (Fig 2J, S3 Table). Five genes were identified that suppress the
MitoMod phenotype (Fig 2C–2E, S4 Table). The suppressor genes function in chromatin
remodelling or transcriptional regulation (Fig 2K, S4 Table). Overall, the variety in function
of genes identified in the screen is consistent with the multifunctional cellular roles of
mitochondria.
To test whether suppression of the mitochondrial dysfunction phenotype in the adult wing
reflects reduced apoptosis, cleaved Drosophila effector caspase (Dcp-1) expression was ana-
lysed in the wing during development. Knock-down of TFAM in the wing causes increased
Dcp-1 expression, but this is reduced to control levels by knock-down of the suppressors iden-
tified in the screen Aop, Ino80, Chrac-14, Ing3 and MTA1-like (S4A–S4I Fig). Moreover,
knock-down of Aop or Ino80 suppress the increase in apoptosis caused by TFAM overexpres-
sion (S4J Fig). These data show that suppression of the adult wing phenotype in MitoMod flies
reflects a reduction in apoptosis.
Inhibition of Ras-ERK-ETS signaling improves function in neurons with a
mitochondrial deficit
The effects of mitochondrial dysfunction are particularly acute in the nervous system and
manipulation of retrograde signaling may be a potential strategy to alleviate these effects. We
aimed to use the wing screen to identify genes involved in mitochondrial retrograde signaling
in the nervous system. Aop (anterior open, also known as Yan), one of the suppressor genes
identified (Fig 2K), is an E-twenty six (ETS) transcription factor and a target of the highly con-
served Ras-ERK (mitogen-activated protein kinase (MAPK)) pathway. Treatment of cultured
neuronal cells with the mitochondrial uncoupler carbonyl cyanide p-(trifluoromethoxy) phe-
nylhydrazone (FCCP) causes aberrant ERK activation [38]. We therefore hypothesised that
Ras-ERK signaling is mis-regulated by mitochondrial dysfunction in the nervous system and
Ras pathway and mitochondrial retrograde signaling
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Fig 2. A genetic modifier screen for the cellular response to mitochondrial dysfunction. (A) Schematic of the genetic screen methodology, see text
for details. (B) Knock-down of TFAM (4217R-1) in a mutant TFAMc01716 heterozygous background in MitoMod flies causes a 45˚ curve at the wing tip.
(C-E) Knock-down of Anterior open (Aop, 3166R-1) (C), chromatin assembly complex 15kDa protein (Chrac-14; 13399R-6) (D) and INO80 complex
subunit (Ino80; GL00616) (E) suppress the MitoMod phenotype. (F-I) Knock-down of phosphoglycerate kinase (Pgk; 110081) (F), Reticulon-like 1
(Rtnl1; 110545) (G), Wnt oncogene analog 5 (Wnt5; 101621) (H) and Adenylate kinase 1 (Adk1; GL00177) (I) enhance the MitoMod phenotype.
Average wing tip angles (n = 3–4) ± S.D are shown, all modifier gene wing angles are significantly different to the MitoMod control (p<0.01). (J) Pie
chart showing the GO biological process of the genes which enhance the MitoMod phenotype. (K) Genes which suppress the MitoMod phenotype.
https://doi.org/10.1371/journal.pgen.1007567.g002
Ras pathway and mitochondrial retrograde signaling
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that manipulation of Ras-ERK signaling would modify the effects of neuronal mitochondrial
dysfunction.
TFAM knock-down in the wing causes similar but weaker effects to TFAM overexpression
(S1J–S1L Fig). We have previously shown that TFAM overexpression in motor neurons causes
a dramatic reduction in pre-synaptic tetramethylrhodamine methyl ester (TMRM) positive
and mitochondrial-GFP labelled mitochondrial number and volume and a robust adult climb-
ing phenotype [36]. Overexpression of TFAM in neurons with D42-Gal4 also causes a failure
of wing inflation in approximately 50% of flies, due to dysfunction of the CCAP neurons that
release the neuropeptide bursicon, which activates wing inflation (S5L–S5N Fig) [36]. TFAM
knock-down in motor neurons also causes a reduction in mitochondrial volume and reduced
adult climbing, but these phenotypes are much weaker than with TFAM overexpression (S5A–
S5G Fig) and TFAM knock-down does not affect wing inflation. We therefore used TFAM
overexpression as a model to test whether targeting Ras/ERK signaling modifies the effects of
mitochondrial dysfunction in neurons. Consistent with the suppressive effect in the screen,
knock-down of Aop in neurons (using a validated RNAi transgene (S5H–S5K Fig)) suppresses
the TFAM overexpression climbing and wing inflation phenotypes (Fig 3A and 3B). Further-
more, knock down of the Ras-ERK pathway components Downstream of raf1 (Dsor; MAPK)
or the MAPK Rolled (Rl; MAPK kinase) both suppressed the TFAM overexpression climbing
and wing inflation phenotypes (S5O–S5V Fig), confirming that inhibition of Ras-ERK signal-
ling alleviates the effects of neuronal mitochondrial dysfunction.
To test whether increasing Aop affects neuronal function we overexpressed Aop alone in
motor neurons, or together with TFAM. Overexpression of Aop in neurons causes a strong
climbing deficit and complete failure of wing inflation (Fig 3C and 3D). Moreover, overexpres-
sion of Aop and TFAM together causes pupal lethality (Fig 3C and 3D), which is not affected
by heterozygosity for the Ras85D loss-of-function allele Ras85DΔC40B, consistent with Aop act-
ing downstream of Ras.
The ETS domain transcription factor pointed (Pnt) is a second target of Ras-ERK signaling
in Drosophila. To test whether reducing Pnt expression also modifies neuronal mitochondrial
dysfunction we used both a validated RNAi targeting Pnt (S6A–S6D Fig) and heterozygosity
for a loss-of-function mutation in pnt (pntΔ88). Knock-down of Pnt in motor neurons, or het-
erozygosity for pnt, suppresses the TFAM overexpression climbing and wing inflation pheno-
types (Fig 3E and 3F, S6E and S6F Fig). Combining Pnt knock-down with heterozygosity for
Ras85D causes significantly increased suppression of TFAM overexpression phenotypes com-
pared to either condition alone (S6G and S6H Fig). However, this is not the case for Aop
knock-down and Ras85DΔC40B (S6I and S6J Fig). Simultaneous knock-down of Pnt and Aop
with TFAM overexpression does not significantly improve the climbing phenotype, but signifi-
cantly improves the wing inflation phenotype compared to TFAM overexpression with Aop
knock-down (S6K and S6L Fig). PntP2 overexpression in motor neurons causes a climbing
deficit and lethality in combination with TFAM overexpression (S6M Fig), which is not
affected by heterozygosity for the Ras85D loss-of-function allele Ras85DΔC40B, consistent with
Pnt acting downstream of Ras. Therefore, reduced expression of the Ras-ERK pathway compo-
nents Aop and Pnt partially overcomes the damaging effects of mitochondrial dysfunction in
motor neurons.
Aop and Pnt are the main transcriptional effectors of the Ras-ERK pathway. To test whether
directly activating Ras modulates neuronal activity in neurons with inhibited mitochondrial
function we used a constitutively active form of Ras, RasV12. Expression of Ras85DV12 in motor
neurons causes lethality with D42-Gal4 and with OK371-Gal4. Knock-down of either Aop or
Pnt suppresses the Ras85DV12 lethality phenotype (S6N and S6O Fig), while Ras85DV12 com-
bined with Aop overexpression is lethal. Therefore, Ras-ERK pathway activation mimics the
Ras pathway and mitochondrial retrograde signaling
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effects of mitochondrial dysfunction and Aop and Pnt both act as positive regulators of the
pathway in motor neurons.
We next looked for direct evidence of Ras-ERK-ETS pathway mis-regulation in neurons
caused by mitochondrial dysfunction. Motor neurons overexpressing TFAM were stained
with an antibody that recognises the activated (di-phosphorylated) form of ERK (dpERK).
dpERK expression is significantly increased in larval motor neurons overexpressing TFAM
(Fig 4). Clonal analysis of TFAM overexpression shows that activation of dpERK is both cell
Fig 3. Knock-down of Aop and Pnt suppress the mitochondrial dysfunction phenotype in neurons. (A,B) Knock-
down of Aop (3166R-1) suppresses the climbing (A) and wing inflation phenotype (B) caused by overexpression of
TFAM using D42-Gal4. (C,D) Aop overexpression with D42-Gal4 causes a severe climbing (C) and wing inflation
phenotype (D) and lethality when overexpressed in combination with TFAM. (E,F) Knock-down of Pnt (JF02227)
suppresses the climbing (E) and wing inflation phenotype (F) caused by overexpression of TFAM with D42-Gal4. Data
are represented as mean +/- SEM, p0.05, p0.01, p0.001. For wing inflation assays the numbers of flies
counted for each genotype are shown in white. Controls are D42-Gal4 hemizygotes.
https://doi.org/10.1371/journal.pgen.1007567.g003
Ras pathway and mitochondrial retrograde signaling
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autonomous and non-cell autonomous (S6P and S6Q Fig). Therefore, Ras-ERK-ETS signaling
is activated in response to mitochondrial dysfunction in Drosophila neurons.
Knock-down of Pnt rescues the active zone phenotype caused by
mitochondrial dysfunction
Similar to mitochondrial dysfunction in late larval sensory neurons, which does not affect
ATP levels due to a compensatory increase in glycolysis [39], overexpression of TFAM in
motor neurons does not alter ATP levels (S7A–S7C Fig). Active zones are the sites of pre-syn-
aptic neurotransmitter release at chemical synapses and are enriched for the protein complexes
that regulate synaptic vesicle release and recycling. TFAM overexpression in motor neurons
causes altered mitochondrial morphology in the cell body, a dramatic loss of pre-synaptic
mitochondria and a reduction in the number of active zones at the larval neuromuscular junc-
tion (NMJ) [36]. Therefore, to further investigate how modulation of Ras-ERK-ETS signaling
affects neuronal mitochondrial dysfunction we focused on the synaptic compartment. Neither
knock-down of Aop or Pnt affects the severe loss of pre-synaptic mitochondria caused by
TFAM overexpression (Fig 5A–5F. S7D and S7E Fig), suggesting that Ras-ERK-ETS pathway
inhibition does not alter the primary mitochondrial defect. Knock-down of Aop does not res-
cue the active zone phenotype caused by TFAM overexpression, but Aop knock-down alone
causes a reduction in active zone number (S7F Fig), complicating the interpretation of this
result. However, knock-down of Pnt fully rescues the active zone phenotype caused by TFAM
overexpression (Fig 5G and 5K). These data show that Ras-ERK-ETS pathway inhibition does
not affect the primary mitochondrial defect, but modifies the active zone phenotype caused by
neuronal mitochondrial dysfunction.
Inhibition of Ras-ERK-ETS signaling improves function in Drosophila
models of mitochondrial disease and Parkinson’s
Mitochondrial dysfunction in humans causes rare primary mitochondrial diseases and is also
associated with more common neurodegenerative diseases, including Parkinson’s. We
Fig 4. Neuronal mitochondrial dysfunction causes increased dpERK expression. (A) The VNC from a control larva expressing CD8-GFP (green) in
motor neurons using OK371-Gal4 stained for dpERK expression (red in A,A’,B,B’, white in A”, B”). (B) The VNC from a larva overexpressing TFAM
using OK371-Gal4 shows increased dpERK expression in motor neurons. (C) Quantification of dpERK expression in motor neuron cell bodies. Data
are represented as mean +/- SEM, p0.01.
https://doi.org/10.1371/journal.pgen.1007567.g004
Ras pathway and mitochondrial retrograde signaling
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Fig 5. Knock-down of Pnt rescues the reduction in active zones caused by mitochondrial dysfunction. (A-D) Segment A3,
muscle 4 NMJ in late third instar larvae from control (A), or with Pnt RNAi (JF02227) (B), TFAM overexpression (C), Pnt
RNAi (JF02227) and TFAM overexpression (D) in motor neurons using OK371-Gal4. Motor neuron specific expression of
mitoGFP (green in (A-D) and white in (A’-D’)) was used to visualise mitochondria and staining for horse radish peroxidase
(red) to visualise neuronal membranes. (E,F) Quantification of mitochondrial number (E) and volume (F). (G-J) Segment A3,
muscle 4 NMJ in late third instar larvae from control (G), Pnt RNAi (JF02227) (H), TFAM overexpression (I), or Pnt RNAi
(JF02227) and TFAM overexpression (J) in motor neurons using OK371-Gal4. Expression of CD8-GFP (GFP, green) is used to
visualise neuronal membranes and brp staining (red in G-J and white in G’-J’) to visualise active zones. (K) Quantification of
active zone number. Data are represented as mean +/- SEM, n.s. not significant, p0.05, p0.01, p0.001. Controls are
OK371-Gal4 hemizygotes.
https://doi.org/10.1371/journal.pgen.1007567.g005
Ras pathway and mitochondrial retrograde signaling
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hypothesised that targeting the retrograde response, through inhibition of Ras-ERK-ETS
signaling, would be beneficial in Drosophila models of human disease associated with mito-
chondrial dysfunction. To test this we used pan-neuronal (nSyb-Gal4) knock-down of the
OXPHOS complex IV subunit Surf1, a model for the primary mitochondrial childhood ence-
phalomyelopathy Leigh syndrome, and park25 homozygous mutant flies, a model for familial
Parkinson’s disease [36, 40, 41]. dpERK expression is increased in the ventral nerve cord
(VNC) by pan-neuronal knock-down of Surf1, but not in park25 homozygous larvae (S7G and
S7H Fig), possibly because of the mild effect of loss of Parkin in neurons. Knock-down of Aop,
knock-down or heterozygosity for pnt all suppress the severe climbing phenotype and rescue
the wing inflation defect caused by pan-neuronal knock-down of Surf1 (Fig 6A–6D, S8A and
S8B Fig). Knock-down of Aop does not significantly improve climbing in the park25 mutant
(S8C Fig). However, heterozygosity for pnt does suppress the climbing phenotype in park25
mutant flies (Fig 6G). To test whether the beneficial effects in these two models are specific to
reduced Aop and Pnt expression, or a general property of Ras-ERK-ETS pathway inhibition,
we used a loss-of-function allele of Ras85D (Ras85DΔC40B). Heterozygosity for Ras85D sup-
presses the climbing and wing inflation defects caused by knock-down of Surf1 (Fig 6E and
6F) and the climbing deficit in park25 homozygous flies (Fig 6H). Thus, targeting the retro-
grade response, through inhibition of Ras-ERK-ETS signaling, improves function in two inde-
pendent models of human disease caused by mitochondrial dysfunction.
Inhibition of Ras-ERK-ETS signaling partially reverses the transcriptional
response to neuronal mitochondrial dysfunction
Mitochondrial dysfunction transcriptionally reprograms cells by altering nuclear gene expres-
sion [22, 29]. It is not known whether this transcriptional reprogramming is protective or
damaging. Ras-ERK-ETS pathway inhibition could benefit neurons either by enhancing the
retrograde transcriptional response, or by reversing the expression of genes that are mis-regu-
lated in response to mitochondrial dysfunction. To understand the mechanism by which Ras-
ERK-ETS signaling alleviates the effects of neuronal mitochondrial dysfunction, we performed
transcriptomic analysis using central nervous system (CNS) tissue from larvae with pan-neu-
ronal TFAM overexpression, Pnt knock-down, Aop knock-down, or TFAM overexpression
combined with Pnt or Aop knock-down. The expression of 606 and 519 genes are significantly
altered by knock-down of Pnt and Aop respectively (Fig 7A, S7 Table). 189 genes were regu-
lated by both Pnt and Aop knock-down and the expression of these genes is strongly positively
correlated (Fig 7B, S8 Table). These transcriptomic data support our epistasis analysis (S6N
and S6O Fig) and are consistent with Pnt and Yan both acting as positive regulators of Ras-
ERK-ETS signaling in neurons.
The expression of 494 genes were significantly altered in control versus TFAM overexpres-
sion conditions, 671 genes in control versus TFAM overexpression combined with Pnt knock-
down and 560 genes in control versus TFAM overexpression combined with Aop knock-
down conditions (Fig 7C, S7 Table). Around a third of these genes are commonly mis-regu-
lated between these conditions and the expression of these common genes is very strongly pos-
itively correlated (Fig 7D and 7E, S9 and S10 Tables). Therefore, the expression of around a
third of genes mis-regulated by TFAM overexpression are unchanged by Pnt or Aop knock-
down. These data show that Pnt or Aop knock-down does not enhance the transcriptional
changes caused by mitochondrial retrograde signaling.
To understand how Pnt and Aop knock-down modify the mitochondrial retrograde
response we directly compared the TFAM overexpression transcriptome to TFAM overexpres-
sion combined with Pnt or Aop knock-down (S7 Table). This comparison shows that in
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Fig 6. Inhibition of Ras-ERK-ETS signaling improves function in Drosophila models of mitochondrial disease and
Parkinson’s. (A,B) Knock-down of Aop (3166R-1) suppresses the climbing (A) and wing inflation phenotype (B)
caused by pan-neuronal knock-down of Surf1 with nSyb-Gal4. (C,D) Heterozygosity for pnt (pntΔ88) suppresses the
climbing (C) and wing inflation phenotype (D) caused by knock-down of Surf1 with nSyb-Gal4. (E,F) Heterozygosity
for Ras85D (Ras85DΔC40B) suppresses the climbing (E) and wing inflation phenotype (F) caused by knock-down of
Ras pathway and mitochondrial retrograde signaling
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combination with TFAM overexpression, Pnt knock-down significantly alters the expression
of 424 genes and Aop knock-down the expression of genes 314, compared to TFAM overex-
pression alone (S7 Table). Of these, 82 genes (TFAM o/e vs TFAM o/e, Pnt RNAi) and 78
genes (TFAM o/e vs TFAM o/e, Aop RNAi) are also mis-regulated in control versus TFAM
overexpression conditions (S11 and S12 Tables). Interestingly, the expression levels of these
genes are strongly negatively correlated (Fig 7F and 7G). Around half of these genes are mis-
regulated by both Pnt and Aop knock-down (S13 Table). Therefore, Pnt or Aop knock-down
reverses the expression of a minor subset of genes that are mis-regulated in response to mito-
chondrial dysfunction. The enriched GO terms for these genes shows that Pnt or Aop knock-
down reverses the expression of a number of functional classes, including transcriptional regu-
lation and transmembrane helix, which may contribute to improved neuronal function (S14
Table). Alternatively, Pnt and Aop knock-down may alleviate the effects of mitochondrial dys-
function through the action of the genes that are regulated independent of retrograde signal-
ling. To test this directly we used RNAi to knock-down Hsc70-2. Hsc70-2 encodes a chaperone
of the heat shock 70 family and is the most strongly upregulated gene in TFAM overexpression
conditions (S7 Table). Knock-down of either Pnt or Aop dramatically reduces the retrograde
induced upregulation of Hsc70-2 expression (S11 and S12 Tables). Knock-down of Hsc70-2 in
motor neurons suppresses the climbing and wing inflation phenotypes caused by TFAM over-
expression (Fig 7H and 7I). These results are consistent with a mechanism whereby inhibition
of Ras-ERK-ETS signaling alleviates the damaging effects of neuronal mitochondrial dysfunc-
tion by reversing the expression of a specific subset of genes within the mitochondrial retro-
grade transcriptome.
Discussion
Fluctuations in mitochondrial activity and function occur during the cell cycle, throughout
development and in disease states. Changes in mitochondrial function affect the cell at multi-
ple levels, but the cellular response to these homeostatic changes is very poorly understood.
We have devised a method to identify genes potentially involved in mitochondrial retrograde
signaling in vivo. The number and function of the genes identified suggests an extensive and
orchestrated cellular response to mitochondrial dysfunction. Inhibition of one of the pathways
identified in the screen, Ras-ERK-ETS signaling, also alleviates the effects of mitochondrial
dysfunction in the Drosophila nervous system. Targeting Ras-ERK-ETS signaling also
improves function in Drosophila models of Leigh syndrome and Parkinson’s. Inhibition of
Ras-ERK-ETS signaling partially reverses the mitochondrial retrograde transcriptional
response, evidence that retrograde signaling contributes to neuronal dysfunction.
Proteomic and genetic methods have been highly successful in characterising the comple-
ment of proteins that make up the mitochondrion [42–44]. Human mitochondria consist of
around 1158 proteins, only 13 of which are encoded by the mitochondrial genome [42]. How-
ever, mitochondria do not function in isolation and participate in a variety of cellular func-
tions, acting within a homeostatic network that responds to changes in the cellular
environment [22]. We have developed a sensitised phenotypic assay in the wing to identify
genes involved in the cellular response to changes in mitochondrial activity. Using this for a
genetic screen we identified 30 modifier genes, the majority of which enhance the wing
Surf1 with nSyb-Gal4. Controls are nSyb-Gal4 hemizygotes. (G,H) Heterozygosity for pnt (G), or Ras85D (H)
suppresses the climbing phenotype in park25 homozygous flies. Controls are w1118. Data are represented as mean +/-
SEM, p0.05, p0.01, p0.001. For wing inflation assays the numbers of flies counted for each genotype are
shown in white.
https://doi.org/10.1371/journal.pgen.1007567.g006
Ras pathway and mitochondrial retrograde signaling
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007567 July 30, 2018 13 / 27
Fig 7. Inhibition of Ras-ERK-ETS signaling partly reverses the transcriptional mis-regulation caused by TFAM overexpression in the nervous
system. (A) Numbers of genes that are mis-regulated by Pnt and Aop knock-down versus control. (B) Correlation of expression levels between genes
mis-regulated in both Pnt and Aop knock-down conditions. (C) Numbers of genes mis-regulated by TFAM overexpression versus control, TFAM
overexpression combined with Pnt knock-down versus control, or TFAM overexpression combined with Aop knock-down versus control. (D)
Correlation of expression levels between genes that were mis-regulated in both TFAM overexpression versus control and TFAM overexpression
combined with Pnt knock-down versus control conditions. (E) Correlation of expression levels between genes that were mis-regulated in both TFAM
overexpression versus control and TFAM overexpression combined with Aop knock-down versus control conditions. (F) Correlation of expression
levels between genes that were mis-regulated in both TFAM overexpression versus control and TFAM overexpression versus TFAM overexpression
combined with Pnt knock-down conditions. (G) Correlation of expression levels between genes that were mis-regulated in both TFAM overexpression
versus control and TFAM overexpression versus TFAM overexpression combined with Aop knock-down conditions. (H,I) Knock-down of Hsc70-2
suppresses the climbing (H) and wing inflation (I) phenotypes caused by TFAM overexpression in motor neurons using D42-Gal4. Data are
represented as mean +/- SEM, n.s. not significant, p0.001. For wing inflation assays the numbers of flies counted for each genotype are shown in
white.
https://doi.org/10.1371/journal.pgen.1007567.g007
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phenotype. It is possible that screening in this way could identify components of the OXPHOS
complexes, or other core mitochondrial proteins. However, knock-down of such genes on
their own in the wing is likely to (and in our experience does) cause a wing phenotype, and so
these genes would be excluded from the screen. We did identify several genes encoding cyto-
solic metabolic proteins (Pgk, Adk1, Pgi) as enhancers of mitochondrial dysfunction, which
did not cause a phenotype when knocked-down by themselves but enhanced the MitoMod
phenotype (S3 Table). However, a key point of this study is that many of the genes identified
have roles in signal transduction and regulation of gene expression, strongly suggesting that
mitochondrial dysfunction modulates the activity of a variety of cell signaling pathways.
The ETS domain transcription factor Aop was identified as a suppressor in the modifier
screen and also suppressed neuronal mitochondrial dysfunction phenotypes. Knock-down or
heterozygosity for pnt also rescued neuronal mitochondrial dysfunction phenotypes. These
results are surprising, as Aop and Pnt generally act antagonistically to each other, with Aop
acting as an inhibitor of Ras-ERK signaling and Pnt as a positive effector. In the canonical
model, activated ERK phosphorylates both Pnt and Aop, promoting cytosolic translocation
and degradation of Aop, as well as enhancing the transcriptional activity of Pnt [45, 46]. In the
wing Pnt and Aop have opposite effects: knock-down of Pnt (using JF02227) enhances, while
knock-down of Aop suppresses the MitoMod phenotype. However, recent systems biology
approaches have shown that the dynamic interplay between Aop and Pnt is more complex
than previously thought and is context dependent [47–49]. Aop stability is in fact regulated dif-
ferentially by Ras-ERK signaling depending on the neuronal differentiation state [49]. We find
that PntP2 and Aop overexpression and expression of a constitutively active form of Ras all
strongly inhibit neuronal function and act synergistically with TFAM overexpression. Knock-
down of either Pnt or Aop suppress Ras-ERK pathway activation and the gene expression
changes caused by Pnt or Aop knock-down in neurons strongly correlate. Moreover, reduced
expression of Ras, Pnt or Aop are protective against the effects of neuronal mitochondrial dys-
function. Aop and Pnt therefore both act as positive effectors of Ras-ERK signaling in motor
neurons and in the context of neuronal mitochondrial dysfunction.
Mitochondrial activity plays a key role in healthy ageing. It was recently shown that inhibi-
tion of Ras, through ubiquitous expression of dominant negative Ras, or Ras knock-down in
adult flies extends lifespan [50]. In contrast to our study, expression of an activated form of
Aop in the gut and fat body of adult flies extended lifespan, while knockdown of Aop in these
tissues had no effect on longevity [50]. The authors did not test whether inhibition of Pnt
affected lifespan, but Pnt overexpression significantly reduced the lifespan of wild-type flies.
Furthermore, administration of a pharmacological agent, Trametinib, which inhibits Ras acti-
vation of ERK kinase, increased Drosophila lifespan. Although there may be differences in
the role of Aop in neuronal mitochondrial dysfunction versus healthy ageing, this previous
study and our work together point to the exciting possibility that inhibition of Ras-ERK-ETS
signaling may be beneficial to both healthy ageing and human diseases associated with mito-
chondrial dysfunction. Our data also suggest that Ras-ERK-ETS signaling acts both cell auton-
omously and non-cell autonomously in response to mitochondrial dysfunction. In the
developing Drosophila eye, Ras-ERK signaling determines cell autonomous photoreceptor cell
fate, acting downstream of the EGF receptor [51]. The secretion of Spitz, the ligand for the
EGFR, from adjacent cells is also regulated by the Ras-ERK pathway [52]. Ras-ERK signaling
thus acts both cell autonomously and non-cell autonomously to control photoreceptor differ-
entiation. Mitochondrial signaling in Drosophila has previously been shown to act through
non-autonomous systemic negative regulation of insulin signaling [53]. The mechanism of
regulation of Ras-ERK-ETS in ageing is not known, nor do we know how mitochondrial dys-
function activates this pathway in neurons. A variety of mitochondrial retrograde signals have
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been identified, including ROS, Ca2+, AMP, nicotinamide adenine dinucleotide (NAD+) and
acetyl coenzyme A [30]. Future studies will identify the factor(s) that mediate mitochondrial
retrograde signaling in the nervous system.
Large scale alterations in transcription in response to mitochondrial dysfunction have been
observed in a wide range of cell types [23]. However, whether these altered transcriptomes
have a functional consequence is not clear. Inhibition of Ras-ERK-ETS signaling restores neu-
ronal function and pre-synaptic active zones in our models but does not appear to affect the
primary mitochondrial defect. This is consistent with our transcriptomic data, which do not
show large scale alterations in the expression of mitochondrial genes with Aop or Pnt Knock-
down. We suggest that the beneficial effects of Ras-ERK-ETS pathway inhibition on mitochon-
drial dysfunction result from transcriptional reprogramming that leads to improvement in
pre-synaptic structure and function.
Reduced expression of Aop or Pnt, transcriptional targets of Ras-ERK signaling, alleviate
the effects of neuronal mitochondrial dysfunction. We exploited this finding to test how the
transcriptome is affected by Aop and Pnt knock-down in the background of mitochondrial
dysfunction. Surprisingly, a significant number of the mitochondrial retrograde transcrip-
tional changes are reversed by Pnt or Aop knock-down. This finding suggests that the tran-
scriptional mis-regulation activated by mitochondrial retrograde signaling at least partly
contributes to neuronal dysfunction. In support of this idea, we find that knock-down of
Hsc70-2, a retrograde response gene whose expression is reduced by Aop and Pnt knock-
down, alleviates neuronal mitochondrial dysfunction phenotypes. Future analyses of these ret-
rograde response genes will help elucidate the cellular mechanisms that contribute to neuronal
dysfunction.
Individual mitochondrial diseases are rare, but in total affect up to 1 in 4300 in the popula-
tion [7]. The nervous system is frequently affected by mitochondrial mutations, resulting in a
wide range of clinical outcomes including ataxia, epilepsy, neuropathy and deafness [54].
Treatments for mitochondrial diseases are limited and mostly symptomatic. Manipulation of
the response to mitochondrial dysfunction in neurons may provide a new potentially curative
strategy for mitochondrial diseases. Ras-ERK signaling has key roles in synaptic plasticity,
learning and memory [55]. However, Ras-ERK-ETS signaling has not previously been identi-
fied as potential therapeutic target for mitochondrial disease. Determining how the transcrip-
tional targets of Ras-ERK-ETS signaling contribute to neuronal dysfunction will provide
important new insight into mitochondrial diseases such as Leigh syndrome.
Materials and methods
Fly strains and growth conditions
Flies were maintained on standard yeast, glucose, cornmeal, agar food at 25˚C in a 12 hour
light/dark cycle unless stated otherwise. For imaging experiments, except AT[NL] and AT
[RK] experiments, embryos were laid over a 24 hour period at 25˚C, incubated for a further 24
hours at 25˚C, then incubated at 29˚C for three days prior to analysis. For AT[NL] and AT
[RK] experiments embryos were laid at 25˚C and larvae maintained at 25˚C until dissection.
Fly stocks were UAS-TFAM3M [36], which was used for all TFAM overexpression experi-
ments except where the weaker UAS-TFAM10M [36] is stated, park25 [40], UAS-Surf123.4
RNAi [41], Ras85DΔC40B [56] and UAS-mito-roGFP2-Grx1 [57]. UAS-ATeam1.03NL (AT[NL])
and UAS-ATeam1.03RK (AT[RK]) flies [39] were from the Kyoto Stock Center (DGRC). The
following fly stocks were from the Bloomington Stock Center: DJ-1α, DJ-1β, Lrrk, parkin and
Pink1 RNAi and overexpression lines (details in S1 Table), w1118, FRT82B, TFAMc01716, Da-
Gal4, nSyb-Gal4, UAS-mitoGFP, MS1096-Gal4,OK371-Gal4,D42-Gal4,UAS-CD8GFP,
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UAS-Aop, UAS-PntP2, pntΔ88, Thor-lacZ (ThorK13517), tub-Gal4, TM6B, tub-Gal80, GMR-Gal4,
UAS-RasV12, TFAMJF02307 and TFAMHMC04965 RNAi lines, DsorHMS00037 and DsorJF01697 RNAi
lines, RlJF1080 and RlHMS00173 RNAi lines. The TFAM RNAi line (NIG, 4217R-1), used in the
MitoMod stock (MS1096-Gal4; TFAM RNAi, TFAMc01716/ TM6B, tub-Gal80), was from the
NIG-Fly Stock Center, Japan. RNAi stocks used in the genetic screen were from the Blooming-
ton Stock Center, the Vienna Drosophila Resource Center [58] and the NIG-Fly Stock Center,
Japan and are listed in S2, S5 and S6 Tables. park25, Ras85DΔC40B and park25, pntΔ88 lines used
in Fig 6 were generated by recombination. Mosaic analysis with a repressible cell marker
(MARCM) analysis of FRT82B, TFAMc01716 was performed using y, w,hs-flp;tub-Gal4,UAS-
mCD8GFP;FRT82B,tub-Gal80 flies as in Avet-Rochex et. al. [59]. Gene names are according to
Flybase [60].
Genetic screen
Virgin female flies carrying the MitoMod genotype balanced with TM6B,tub-Gal80
(MS1096-Gal4; TFAM RNAi,TFAMc01716/TM6B,tub-Gal80)were crossed to males carrying
RNAi transgenes. 1–2 days after eclosion of the progeny wings were observed and scored in
males. RNAi lines were only classed as enhancers if most flies had a90ᵒ wing curve. RNAi
lines were classed as suppressors if most flies had a <45ᵒ wing curve (S2 Table). Crosses from
RNAi lines that enhanced or suppressed the MitoMod wing phenotype were repeated to con-
firm the result. To exclude RNAi lines that cause a phenotype by themselves, MS1096-Gal4 vir-
gin females were crossed to all RNAi lines. If the progeny of this cross had a wing phenotype
then the RNAi line was omitted from the MitoMod screen (S2 Table). Genes for all interacting
RNAi lines were tested with independent RNAi lines, where available (S2 Table), and only
classed as positive hits if the phenotype was replicated by the independent RNAi (S5 and S6
Tables).
RNAi lines were selected using gene expression data available on FlyAtlas, to select genes
that are expressed more strongly in the brain than in the whole body [61]. RNAi lines for Dro-
sophila chromatin remodelling genes were also used [62]. GO analysis of genes identified in
the screen was performed using the Panther Classification System [63].
Behavioral analysis
Climbing assays were performed as previously described [36]. Males were used for all climbing
assays, apart from experiments involving knock-down of Surf1, where females were used for
all genotypes.
To quantify wing inflation, flies were transferred into a new vial after eclosion and left for at
least 24 hours to allow time for normal wing inflation to occur. Numbers of flies with fully
inflated, semi-inflated and uninflated wings were then recorded. All flies that eclosed from the
vial were counted. Statistical analysis was performed on raw data and data displayed as a
percentage.
Immunofluorescence and imaging
Tissues were prepared, imaged and quantified as previously described [36]. Primary antibodies
were Drosophila anti-TFAM (Abcam, 1/500), rabbit anti-Dcp1 (Cell Signaling, 1/200), mouse
anti-Wingless (DSHB, 1/200), chicken anti-β galactosidase (Abcam ab9361, 1:1000), mouse
anti-Aop (DSHB, 1/200), mouse anti-brp (DSHB, 1/200), rabbit anti-dpErk1/2 (Cell Signaling,
1/200), HRP-Cy3 (Stratech, 1/1000), rat anti-PntP2 (1/500) [64]. Secondary antibodies were
AlexaFlour 488, AlexaFlour 594 and AlexaFlour 633 (Invitrogen, 1/1000). All images were
taken using a Zeiss LSM710 confocal microscope with Zen software. Imaging of controls and
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experimental samples in each experiment was performed using identical confocal microscope
settings. Mitochondrial number and volume were quantified using Volocity (Perkin Elmer),
15μm x 15μm (xy), 5 μm (z). dpERK expression was quantified in ImageJ using the Point and
Measure tools. Dcp1 expression was quantified using Volocity (PerkinElmer) using image pro-
jections. To quantify Dcp1 expression in the wing disc the dorsal compartment was selected as
the area between the wingless expressing dorsoventral boundary and the third fold in the
hinge area of the wing disc. MARCM analysis was performed as in Avet-Rochex et. al. [59].
For Fo¨rster resonance energy transfer (FRET)–based ATP biosensor imaging, AT[NL] ATP
biosensor expressing and AT[RK] ATP insensitive expressing control wing imaginal discs or
larval CNS tissues were dissected in Schneider’s medium (Thermo Scientific) and imaged
immediately at 21˚C using a 458nm excitation laser and detecting emitted light between 460-
499nm (CFP) and 535-650nm (FRET) using a Zeiss LSM 710 confocal microscope. For control
experiments wing imaginal discs were incubated in Schneider’s medium with 100μM oligomy-
cin (VWR)/50 mM 2-deoxyglucose (SLS) for 40 minutes at 21˚C, then imaged immediately in
the same medium. CFP and FRET channel signal intensity at the same three randomly selected
points in each wing disc, or three cell bodies in each VNC, was determined using the ImageJ
Point and Measure tools and used to calculate the FRET/CFP ratio as a measure of ATP levels
[39]. Imaging using Mito-roGFP2-Grx1 was performed as described previously [36]. For DHE
staining, wing discs were incubated in 2μM DHE (Cambridge Bioscience) in Schneider’s
medium for 10 minutes, rinsed twice in Schneider’s medium, then fixed for 5 minutes in 4%
formaldehyde/PBS, washed briefly in PBS, dissected and imaged.
ATP luciferase assay
20 wing imaginal discs per genotype were dissected in PBS, homogenized in 100μl extraction
buffer (6M guanidine chloride, 100mM TrisHCL, 4mM EDTA, pH 8.0) and incubated at 70˚C
for 5 mins. ATP levels were measured using the ATP Determination kit (Molecular Probes)
according to the manufacturer’s instructions.
Western blot analysis
Western blot analysis was performed as previously described [36]. Primary antibodies were
diluted in TBS/0.1% Tween 20 (TBS-T) and incubated overnight at 4˚C and were Drosophila
anti-TFAM (Abcam, 1/500), mouse anti-ATP5A (Abcam, 1/5000), mouse anti-MTCO1
(Abcam, 1/1000) and rabbit anti-Actin (Cell Signaling, 1/4000). After three ten minute washes
in TBS-T, the membranes were incubated for 90 minutes with fluorescently labelled secondary
antibodies (anti-mouse IRdye 680 and anti-rabbit IRdye 800, LI-COR, both at 1/5000) diluted
in TBS-T, then washed three times for ten minutes in TBS-T. The membranes were then
scanned and analysed using an Odyssey infrared scanner (LI-COR). Odyssey infrared imaging
systems application software version 3.0.25 was used to quantify the intensity of the bands on
the blots. Normalised expression level was calculated by determining the band intensity rela-
tive to Actin.
Quantitative PCR
qRT-PCR and qPCR of mtDNA were performed as previously described [36]. Primers used
for qRT-PCR were ThorFwd: CGAGGTGTACTCCTCGACGC and ThorRvs: GAGCCACGG
AGATTCTTCATGA; Hsp22Fwd: AGCGTTGTCCTGGTGGAG and Hsp22Rvs: GAGCTAT
AGCCACCTTGTTCG; Rpl4Fwd: TCCACCTTGAAGAAGGGCTA and Rpl4Rvs: TTGCGG
ATCTCCTCAGACTT.
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Microarray experiments and analysis
CNS tissue from 20 late third instar larvae per genotype were dissected in cold PBS and trans-
ferred directly into 100μl lysis buffer containing β-mercaptoethanol (Absolutely RNA Micro-
prep kit, Agilent Technologies). The lysis buffer was kept on ice while all the brains were
dissected. RNA was prepared following manufacturer’s instructions, including DNase treat-
ment and stored at -80˚C. Samples were prepared in triplicate.
RNA was measured for quantity and integrity on an RNA Pico Chip (Agilent Technolo-
gies). 10ng of RNA per genotype was converted into labelled cDNA with the Nugen Ovation
System V2 (NuGEN Technologies Inc.). 7mg of labelled cDNA was hybridised to Affymetrix
Drosophila genome v2 GeneChips for 20 hours at 45˚C. They were then washed, stained (Gen-
eChip Fluidics Station 450) and scanned (GeneChip Scanner 3000 7G) according to the manu-
facturer’s instructions (Nugen Technologies Inc & Affymetrix).
Microarray data was processed using the MAS5.0 algorithm using the Transcriptome Anal-
ysis Console (ThermoFisher). Means were calculated using Tukey’s Bi-weight average algo-
rithm and differential expression between groups was calculated using un-paired one way
analysis of variance (ANOVA). A statistical cutoff of p<0.05 and a fold change cutoff of ±1.5
fold were used. Correlations between datasets were analysed using GraphPad Prism (Graph-
Pad Software Inc.). The data discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series accession number GSE114054.
GO analysis was performed using DAVID (the database for annotation, visualization and inte-
grated discovery) bioinformatics resources [65].
Statistical analyses
GraphPad Prism (GraphPad Software Inc.) was used to create graphs and for statistical analy-
sis. Data with a p-value less than or equal to 0.05 was considered significant. Comparisons of
two samples of continuous data were analysed with an unpaired, two-tailed student’s t-test,
where appropriate. Data were analysed for normality using the D’Agostino & Pearson omni-
bus normality test. Data that did not pass the normality test were analysed with the Mann
Whitney test. Variance of the samples was assessed with an F test. If the variances of the two
samples were significantly different then the Welch’s correction was applied to the t-test. In
order to compare more than two samples of continuous data, one-way ANOVA was used with
Tukey’s post hoc test. If data did not pass the D’Agostino & Pearson omnibus normality test,
the Kruskal-Wallis, followed by Dunn’s post hoc test were utilised. Categorical data were ana-
lysed using chi-squared.
Supporting information
S1 Fig. TFAM knockdown causes loss of mtDNA and mitochondrial gene expression.
(A) qPCR of mtDNA copy number from late third instar larvae with ubiquitous knock-down
of TFAM (4217R-1) using tub-Gal4. Controls are tub-Gal4 hemizygotes. (B) Western analysis
of coxI, ATP synthase α and TFAM expression from late third instar larvae control (tub-
Gal4/+, lanes 1–3), or with ubiquitous knock-down of TFAM using tub-Gal4 (lanes 4–6).
(C-E) Quantification of coxI, ATP synthase α and TFAM expression. (F,G) TFAM staining in
wing imaginal discs with TFAM knock-down (4217R-1) (F) or TFAM overexpression (G)
using MS1096-Gal4. Arrows mark the dorso-ventral compartment boundary (dorsal is up).
Scale bar: 10μm. (H) A MARCM clone in the late third instar larval wing imaginal disc show-
ing that cells that are homozygous of TFAMc01716 (expressing GFP, green) have strongly
reduced levels of TFAM expression (red in H, white in H’). (I-L) TFAM overexpression (using
TFAM10M grown at 18˚C to reduce Gal4 activity), or knock-down of TFAM using two
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independent RNAi lines (TFAMJF02307 and TFAMHMC04965) in the wing using MS1096-Gal4
cause a curved wing phenotype. (M-P) The curved wing phenotype caused by knock-down of
TFAM using MS1096-Gal4 and heterozygosity for TFAMc01716 (M,O) is almost completely
rescued by co-expression of TFAM in both males (N) and females (P).
(TIF)
S2 Fig. TFAM knock-down and overexpression alter mitochondrial morphology but do
not affect ATP levels in the developing wing. (A-C) The FRET/CFP fluorescence emission
ratio of the AT[NL] FRET–based ATP biosensor expressed in the wing imaginal disc using
MS1096-Gal4 is decreased when the tissue is incubated with oligomycin (OM)/2-deoxyglu-
cose. (D-F) The FRET/CFP fluorescence emission ratio of the AT[RK] control protein, which
does not bind ATP, is unchanged when the tissue is incubated with oligomycin (OM). (G-J)
Knock-down (4217R-1) or overexpression of TFAM do not alter the FRET/CFP fluorescence
emission ratio of the AT[NL] FRET–based ATP biosensor in the wing disc. Images show a
merge of the CFP (green) and FRET (red) channels. (K) ATP luciferase assay of wing discs
with TFAM RNAi and overexpression using MS1096-Gal4. (L-N) Ratio images show no
change in mitochondrial glutathione redox potential reporter mito-roGFP2-Grx1 fluorescence
after excitation at 405nm (red) and 488nm (green) in wing discs with TFAM knock-down and
overexpression using MS1096-Gal4. (O) Quantification of mito-roGFP2-Grx1 fluorescence
ratio. (P-R) DHE staining in MS1096-Gal4 hemizygous control (P), TFAM knock-down (Q)
and overexpression (R) wing discs. (S) Quantification of DHE staining in the dorsal compart-
ment of the wing disc. (T-V) Mitochondrial morphology with TFAM knock-down (U) and
TFAM overexpression (V) in the wing imaginal disc using MS1096-Gal4, compared to control
(T). Mito-GFP is used to label mitochondria. Scale bar: 10 μm. (W,X) Quantification of mito-
chondrial number (W) and volume (X) in wing imaginal discs. (Y,Z) qRT-PCR of Thor (Y)
and Hsp22 (Z) mRNA expression in wing imaginal discs with TFAM knock-down and TFAM
overexpression using MS1096-Gal4. Data are represented as mean +/- SEM, n.s. not signifi-
cant, p0.05, 0.01, p0.001, a.u. arbitrary units.
(TIF)
S3 Fig. Modulation of genes associated with Parkinson’s disease enhance the MitoMod
wing phenotype. (A) MS1096-Gal4, + control male. (B) Male progeny from MitoMod fly
crossed to w1118 showing the 45˚ curve at the wing tip. (C-H) Male progeny from crosses of
MitoMod with DJ-1α RNAi (HMJ21180) (C), DJ-1α overexpression (D), DJ-1β RNAi
(HMS01915) (E), DJ-1β overexpression (F), Lrrk RNAi (HMS00456) (G), Pink1 overexpres-
sion (H).
(TIF)
S4 Fig. Knock-down of Aop or Ino80 abrogates the increased apoptosis phenotype caused
by knock-down of TFAM. (A) A wing disc from a MS1096-Gal4, + larva stained for Dcp1
expression and DAPI. (B,C) Wing discs from larvae with knock-down of Ino80 and Aop using
MS1096-Gal4. (D) A wing disc from the progeny of MitoMod crossed to w1118. (E,F) Wing
discs from the progeny of MitoMod crossed to Ino80 RNAi (E) and Aop RNAi (F). (G,H)
Quantification of Dcp1 expression. Dcp1 expression is shown in green in (A)-(F) and white in
(A’)-(F’) and DAPI staining shown in blue. Dotted line marks the dorso-ventral compartment
boundary (dorsal is bottom left). (I) Quantification of Dcp1 expression in MitoMod wing discs
combined with knock-down of Chrac-14, Ing3 and MTA1-like. (J) Quantification of Dcp1
expression in wing discs overexpressing TFAM combined with knock-down of Ino80 or Aop.
Data are represented as mean +/- SEM, n.s. not significant, p0.05, p0.001.
(TIF)
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S5 Fig. Knock-down of TFAM in motor neurons causes weak mitochondrial loss and climb-
ing phenotypes. (A-C) Segment A3, muscle 4 NMJ in late third instar larvae from control (A),
with TFAM RNAi (4217R-1) (B), or TFAM overexpression (C) in motor neurons using OK371-
Gal4. Motor neuron specific expression of mitoGFP (green in (A-C) and white in (A’-C’)) was
used to visualise mitochondria and staining for horse radish peroxidase (red) to visualise neuro-
nal membranes. (D,E) Quantification of mitochondrial number (D) and volume (E). (F,G)
Knock-down of TFAM (4217R-1) using either OK371-Gal4 (F) or D42-Gal4 (G) causes reduced
climbing ability in adults, but this phenotype is weaker than with TFAM overexpression. (H,I)
An eye imaginal disc from a control GMR-Gal4/+ larva (H), or a larva expressing Aop RNAi
(3166R-1) using GMR-Gal4 (I), which shows almost complete loss of Aop expression in photo-
receptor neurons posterior to the morphogenetic furrow (arrow), where GMR-Gal4 is expressed
(posterior is to the right). (J,K) Adult eyes from GMR-Gal4/+ control (J), or GMR-Gal4/Aop
RNAi (3166R-1) (K) flies showing a rough eye phenotype caused by Aop knock-down. (L-N)
Overexpression of TFAM with D42-Gal4 causes wings to either inflate normally (L), semi-
inflate (M) or fail to inflate (N) in around 50% of flies. (O-R) Knock-down of Dsor using inde-
pendent RNAi lines (HMS00037 and JF01697) suppresses the climbing (O,Q) and wing infla-
tion phenotypes (P,R) caused by TFAM overexpression with D42-Gal4. (S-V) Knock-down of
Rl using independent RNAi lines (JF1080 and HMS00173) suppresses the climbing (S,U) and
wing inflation phenotypes (T,V) caused by TFAM overexpression with D42-Gal4. The numbers
of flies counted for each genotype are shown in white. Data are represented as mean +/- SEM,
n.s. not significant, p0.05, 0.01, p0.001. Controls are Gal4 hemizygotes.
(TIF)
S6 Fig. TFAM overexpression climbing and wing inflation phenotypes are suppressed by
heterozygosity for Pnt. (A,B) An eye imaginal disc from a control GMR-Gal4/+ larva (A), or
a larva expressing Pnt RNAi (JF02227) using GMR-Gal4 (B), which shows almost complete
loss of PntP2 expression in photoreceptor neurons posterior to the morphogenetic furrow
(arrow). Posterior is to the right. (C,D) Adult eyes from GMR-Gal4/+ control (C), or
GMR-Gal4/Pnt RNAi (JF02227) (D) flies showing a rough eye phenotype caused by Pnt
knock-down. (E) The reduced climbing ability of flies with TFAM overexpression using
D42-Gal4, is suppressed in a pntΔ88 heterozygous background. (F) The wing inflation pheno-
type caused by overexpression of TFAM with D42-Gal4 is suppressed in a pntΔ88 heterozygous
background. The numbers of flies counted for each genotype are shown in white. (G,H)
Knock-down of Pnt combined with heterozygosity for Ras85D suppresses the climbing (G)
and wing inflation phenotypes (H) caused by TFAM overexpression with D42-Gal4 compared
to either condition alone. (I,J) Knock-down of Aop combined with heterozygosity for Ras85D
does not affect the climbing (I) and wing inflation phenotypes (J) caused by TFAM overexpres-
sion with D42-Gal4 compared to either condition alone. (K,L) Knock-down of Pnt and Aop
together does not affect the climbing (K), but suppresses the wing inflation phenotype (L)
caused by TFAM overexpression with D42-Gal4 compared to Aop knock-down alone. (M)
Overexpression of PntP2 in motor neurons with D42-Gal4 causes reduced climbing and is
lethal when combined with TFAM overexpression. (N,O) Knock-down of Aop (N) or Pnt (O)
rescues the lethality caused by expression of Ras85DV12 with OK371-Gal4. Controls are
D42-Gal4 hemizygotes. Data are represented as mean +/- SEM, n.s. not significant, p0.05,
 p0.01 p0.001. (P,Q) Mosaic analysis with a repressible cell marker (MARCM) control
(P) or TFAM overexpression (Q) clones (green) stained for dpERK expression (red).
(TIF)
S7 Fig. Knock-down of Aop does not affect the synaptic mitochondrial loss caused by
mitochondrial dysfunction. (A-C) Overexpression of TFAM does not alter the FRET/CFP
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fluorescence emission ratio of the AT[NL] FRET–based ATP biosensor expressed in motor
neurons with OK371-Gal4. Images show a merge of the CFP (green) and FRET (red) chan-
nels. Data are represented as mean +/- SEM, a.u. arbitrary units. (D,E) Quantification of
mitochondrial number (D) and volume (E) from segment A3, muscle 4 NMJ in late third
instar larvae from control, or with Aop RNAi (3166R-1), TFAM overexpression, or Aop
RNAi (3166R-1) and TFAM overexpression together in motor neurons using OK371-Gal4.
(F) Quantification of active zone number from the same genotypes as in (D,E). Controls
are OK371-Gal4 hemizygotes. (G) dpERK expression is increased in the VNC by pan-
neuronal knock down of Surf1 with nSyb-Gal4, compared to hemizygous nSyb-Gal4 con-
trols. (H) dpERK expression is unchanged in the VNC in park25 larvae compared to w1118
controls. Data are represented as mean +/- SEM, n.s. not significant, p0.05,  p0.01,
p0.001.
(TIF)
S8 Fig. Knock-down of Pnt rescues the Surf1 RNAi phenotype. (A,B) Knock down of Pnt
rescues the climbing (A) and wing inflation (B) phenotypes causes by knock-down of Surf1
with nSyb-Gal4. (C) The climbing defect in park25 male flies is not improved by ubiquitous
knock-down of Aop (3166R-1) using Da-Gal4. Controls are w1118. Data are represented as
mean +/- SEM, n.s not significant, p0.01, p0.001.
(TIF)
S1 Table. Enhancement of the MitoMod wing phenotype by knock-down of familial Par-
kinson’s disease genes.
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